Articles From: Xencor and Novo Nordisk Enter Discovery Collaboration Using Xencor's XmAb Bispecific and Immune Inhibitor Technologies to Xerium to Present at Sidoti Institutional Investor Forum January 12, 2015


2015/2/19
Conference call to be held today at 4:30 p.m. ET MONROVIA, Calif.
Sign-up for Xencor Reports Fourth Quarter and Full Year 2014 Financial Results investment picks
2015/1/29
-33% rate of DAS28-CRP remission or low disease activity reported in Phase 2a cohort- -Autoimmune disease-modifying activity demonstrated by targeting FcgRIIb (CD32b)- -Clinical trial for rare autoimmune disorder IgG4-related disease (IgG4-RD) planned for 2015- -Conference call today at 8:30 a.m. ET- MONROVIA, Calif.
Sign-up for Xencor Reports Top-line XmAb®5871 Phase 1b/2a Results Showing Promising Clinical Activity in Rheumatoid Arthritis investment picks
2015/1/29
- 90% of subjects had reduction of free IgE to below the limit of detection by the end of XmAb7195 infusion, including at lowest dose evaluated of 0.3 mg/kg - - Dose limiting toxicity of thrombocytopenia observed at 3.0 mg/kg - - Enrollment continues in Part 2 of trial for high IgE subjects - - Conference call today at 8:30 a.m. ET - MONROVIA, Calif.
Sign-up for Xencor Reports XmAb®7195 Top-line Interim Phase 1a Results Showing Rapid Reduction of Serum IgE in Healthy Volunteers investment picks
2014/12/4
MONROVIA, Calif.
Sign-up for Xencor to Present at the 25th Annual Oppenheimer & Co. Healthcare Conference investment picks
2015/2/5
MONROVIA, Calif.
Sign-up for Xencor to Webcast Presentations at Two Upcoming Conferences in February investment picks
2015/2/23
MONROVIA, Calif.
Sign-up for Xencor, Inc. Announces Proposed Public Offering of Common Stock investment picks
2015/2/12
MONROVIA, Calif.
Sign-up for Xencor, Inc. to Host Fourth Quarter and Full Year 2014 Financial Results Webcast and Conference Call investment picks
2015/2/24
ORLANDO, Fla.
Sign-up for Xenia Hotels & Resorts Announces Preliminary Full Year 2014 Results and Reaffirms 2015 Guidance investment picks
2015/2/18
RICHMOND, Va., Feb.
Sign-up for Xenith Bankshares, Inc. Reports 2014 Results, Strong Loan and Deposit Growth investment picks
2015/1/8
BURNABY, British Columbia, Jan.
Sign-up for Xenon Pharmaceuticals Outlines Key Anticipated Milestones for 2015 investment picks
2014/12/15
BURNABY, British Columbia, Dec.
Sign-up for Xenon Pharmaceuticals Reports Third Quarter 2014 Financial Results investment picks
2015/2/19
BURNABY, British Columbia, Feb.
Sign-up for Xenon Pharmaceuticals' Partner Teva to Initiate Phase 2b Clinical Trial of TV-45070 in Post-Herpetic Neuralgia investment picks
2015/1/29
XenoPort, Inc. (NASDAQ: XNPT) announced today the pricing of $100 million aggregate principal amount of 2.50% Convertible Senior Notes due 2022 in a private placement to qualified institutional buyers pursuant to Rule 144A (the “offering”) under the Securities Act of 1933, as amended (the “Securities Act”). In connection with the offering, XenoPort also granted the initial purchasers of the notes a 30-day option to purchase up to an additional $15 million aggregate principal amount of the notes to cover over-allotments, if any.
Sign-up for XenoPort Announces Pricing of $100 Million 2.50% Convertible Senior Notes due 2022 investment picks
2015/1/28
XenoPort, Inc. (Nasdaq: XNPT) announced today that it intends to offer, subject to market and other conditions, $100 million aggregate principal amount of convertible senior notes due 2022 in a private placement to qualified institutional buyers pursuant to Rule 144A (the “offering”) under the Securities Act of 1933, as amended (the “Securities Act”). In connection with the offering, XenoPort expects to grant the initial purchasers of the notes a 30-day option to purchase up to an additional $15 million aggregate principal amount of the notes from XenoPort to cover over-allotments, if any.
Sign-up for XenoPort Announces Proposed Offering of $100 Million Convertible Senior Notes due 2022 investment picks
2015/1/11
XenoPort (NASDAQ:XNPT) today reported an update on prescription trends and further development of HORIZANT ® (gabapentin enacarbil) Extended-Release Tablets, including feedback from the U.S. Food and Drug Administration (FDA) on development for treatment of alcohol use disorder (AUD). HORIZANT prescription trend highlights include: The number of nation-wide prescribed tablets for the 13 weeks ending December 19, 2014 was 1,256,082, an increase of 18% compared to the prior 13 weeks ending September 19, 2014 and an increase of 95% over the 13-week period ending December 20, 2013.* The rolling four-week average of prescribed tablets for the week ending December 19, 2014 was 100,742.* The current wholesale acquisition cost (WAC) price is $7.69 per tablet.
Sign-up for XenoPort Provides Highlights of HORIZANT Prescription Trends and Update on Development for Alcohol Use Disorder investment picks
2015/2/19
XenoPort, Inc. (Nasdaq:XNPT) announced today its financial results for the fourth quarter and year ended December 31, 2014.
Sign-up for XenoPort Reports Fourth Quarter and Year-End 2014 Financial Results investment picks
2015/2/23
XenoPort, Inc. (NASDAQ: XNPT) announced today that it will provide access via the World Wide Web to its presentation at the Cowen and Company 35th Annual Health Care Conference.
Sign-up for XenoPort to Present at the Cowen and Company 35th Annual Health Care Conference investment picks
2015/2/18
XenoPort, Inc. (Nasdaq: XNPT) announced today that it will provide access via the World Wide Web to its presentation at the RBC Capital Markets’ Global Healthcare Conference.
Sign-up for XenoPort to Present at the RBC Capital Markets’ Global Healthcare Conference investment picks
2015/2/4
YOUNGSVILLE, N.C., Feb.
Sign-up for Xerium Announces Analyst Coverage Initiated by Macquarie Capital investment picks
2015/1/14
YOUNGSVILLE, N.C., Jan.
Sign-up for Xerium Announces Two Plant Expansion Projects in Roll Cover and Mechanical Services Business investment picks
2014/12/5
YOUNGSVILLE, N.C., Dec.
Sign-up for Xerium Introduces Huyperm ES and ProSeam ES Enhanced Surface Felt Technology for High Quality Paper and Paperboard Machines investment picks
2014/12/2
YOUNGSVILLE, N.C., Dec.
Sign-up for Xerium Introduces HuySpeed QS Tissue Felt Technology investment picks
2014/12/10
YOUNGSVILLE, N.C., Dec.
Sign-up for Xerium Introduces Hyperstar XLS Roll Cover Technology for Heavy Coat Weight Applications investment picks
2014/12/12
YOUNGSVILLE, N.C., Dec.
Sign-up for Xerium Introduces New Generation Genesis XTi and Genesis APi Calender Roll Cover Technology investment picks
2014/12/5
YOUNGSVILLE, N.C., Dec.
Sign-up for Xerium Introduces ProSeam 3L Seam Felt Technology for Demanding Paper and Paperboard Machines investment picks
2014/12/4
YOUNGSVILLE, N.C., Dec.
Sign-up for Xerium Introduces ProSeam CL Felt Technology for Cylinder Board Machines investment picks
2014/12/29
YOUNGSVILLE, N.C., Dec.
Sign-up for Xerium Named by Triangle Business Journal as One of the Top 35 Healthiest Employers for 2014 investment picks
2015/2/6
YOUNGSVILLE, N.C., Feb.
Sign-up for Xerium Schedules Fourth Quarter and Year-End 2014 Conference Call investment picks
2015/1/5
YOUNGSVILLE, N.C., Jan.
Sign-up for Xerium to Present at Sidoti Institutional Investor Forum January 12, 2015 investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Xencor and Novo Nordisk Enter Discovery Collaboration Using Xencor's XmAb Bispecific and Immune Inhibitor Technologies to Xerium to Present at Sidoti Institutional Investor Forum January 12, 2015
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent